This study was performed by Grupo de Estudos da Doença Inflamatória Intestinal do Brasil - GEDIIB, Brasil.
Arq Gastroenterol. 2020 Oct-Dec;57(4):416-427. doi: 10.1590/S0004-2803.202000000-77.
Inflammatory bowel diseases (IBD) are chronic inflammatory affections of recurrent nature whose incidence and prevalence rates have increased, including in Brazil. In long term, they are responsible for structural damage that impacts quality of life, morbidity and mortality of patients.
To describe the profile of physicians who treat IBD patients as well as the characteristics of IBD care, unmet demands and difficulties.
A questionnaire containing 17 items was prepared and sent to 286 physicians from 101 Brazilian cities across 21 states and the Federal District, selected from the register of the State Commission of the "Study Group of Inflammatory Bowel Disease of Brazil" (GEDIIB).
The majority of the physicians who answered the questionnaire were gastroenterologists and colorectal surgeons. More than 60% had up to 20 years of experience in the specialty and 53.14% worked at three or more locations. Difficulties in accessing or releasing medicines were evident in this questionnaire, as was referrals to allied healthy professionals working in IBD-related fields. More than 75% of physicians reported difficulties in performing double-balloon enteroscopy and capsule endoscopy, and 67.8% reported difficulties in measuring calprotectin. With regard to the number of patients seen by each physician, it was shown that patients do not concentrate under the responsibility of few doctors. Infliximab and adalimumab were the most commonly used biological medicines and there was a higher prescription of 5-ASA derivatives for ulcerative colitis than for Crohn's disease. Steroids were prescribed to a smaller proportion of patients in both diseases. The topics "biological therapy failure" and "new drugs" were reported as those with higher priority for discussion in medical congresses. In relation to possible differences among the country's regions, physicians from the North region reported greater difficulty in accessing complementary exams while those from the Northeast region indicated greater difficulty in accessing or releasing medicines.
The data obtained through this study demonstrate the profile of specialized medical care in IBD and are a useful tool for the implementation of government policies and for the Brazilian society as a whole.
炎症性肠病（IBD）是一种反复发作的慢性炎症性疾病，其发病率和患病率都有所增加，包括在巴西。长期以来，它们会导致结构损伤，从而影响患者的生活质量、发病率和死亡率。
描述治疗 IBD 患者的医生的特征以及 IBD 护理的特点、未满足的需求和困难。
编制了一份包含 17 个项目的问卷，并发送给来自巴西 21 个州和联邦区的 101 个城市的 286 名医生，这些医生是从巴西炎症性肠病研究组（GEDIIB）的州委员会登记处选出的。
回答问卷的医生多数为胃肠病学家和结直肠外科医生。超过 60%的医生在该专业有长达 20 年的经验，53.14%的医生在三个或更多地点工作。在这份问卷中，明显存在获取或释放药物以及向从事与 IBD 相关领域的联合健康专业人员转诊的困难。超过 75%的医生报告在进行双气囊小肠镜和胶囊内镜检查方面存在困难，67.8%的医生报告在测量钙卫蛋白方面存在困难。关于每位医生所看患者的数量，结果表明患者不会集中在少数医生的负责下。英夫利昔单抗和阿达木单抗是最常用的生物药物，用于溃疡性结肠炎的 5-ASA 衍生物的处方比用于克罗恩病的更多。两种疾病中都有较小比例的患者使用了类固醇。在医学会议上，“生物治疗失败”和“新药”被报告为具有更高讨论优先级的主题。关于该国各地区之间可能存在的差异，来自北部地区的医生报告在获取补充检查方面存在更大困难，而来自东北部地区的医生则表示在获取或释放药物方面存在更大困难。
通过这项研究获得的数据展示了 IBD 专科医疗护理的概况，是实施政府政策以及对整个巴西社会的有用工具。
